Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

20.03 -0.20 (-0.99%)
Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
29 30 Next >
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why Teva Pharmaceutical Stock Is Sliding Today
Investors were disappointed with the drugmaker's 2023 outlook. 
Via The Motley Fool
Teva Pharmaceutical Stock Dives On Fourth-Quarter Miss, Light 2023 Guidance
The company missed fourth-quarter estimates and issued light guidance. 
Via Investor's Business Daily
Analyst Ratings for Teva Pharmaceutical Indus
 
Via Benzinga
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
From Teva Pharmaceutical Industries Limited
Via Business Wire
Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday
With US futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug
Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug. 
Via InvestorPlace
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
The company only just gained approval for its depression drug in August. 
Via Investor's Business Daily
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharmaceutical Industries (TEVA) Q4 2022 Earnings Call Transcript
TEVA earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations
 
Via Benzinga
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026
These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite. 
Via The Motley Fool
The 7 Best Growth Stocks to Buy for February 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
Things aren't as bad as they might seem. 
Via The Motley Fool
6 Great Stocks to Buy in 2023 and Hold Forever
I own all six great businesses and don't plan to sell a single share. 
Via The Motley Fool
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback
Catalyst is adding to its portfolio with a $160 million deal. 
Via Investor's Business Daily
Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025
A 33% plunge in the Nasdaq Composite is the opportune time to scoop up these exceptional deals. 
Via The Motley Fool
Dow, Nasdaq Boasting Triple-Digit Midday Lead
Investors seem intent on leaving last week's losses behind, as earnings season heats up. 
Via Talk Markets
Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product
 
Via Benzinga
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
 
Via Benzinga
Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday
JP Morgan cut the price target for Apple Inc. (NASDAQ: AAPL) from $190 to $180. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to $133.70 in pre-market... 
Via Benzinga
Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Organon Stock Scores Market Leadership With Jump To 83 RS Rating
Organon sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.